Each product below lists per-product conditions (indications, exclusions, required medical information, age restrictions, prescriber restrictions, coverage duration, other criteria, prerequisite therapy).
Adapalene GEL: Indications: Indications; Off-Label Uses: Off-Label Uses; Age Restrictions: N/A; Prescriber Restrictions: N/A; Coverage Duration: 1 YEAR; Prerequisite Therapy Required: Criteria DOES NOT require use of a prerequisite Part D drug.
Adbry: Indications: All Medically-accepted Indications; Age: at least 12 years; Coverage Duration: 1 YEAR; Exclusion: Cannot be used in combination with another biologic or targeted DMARD for same condition; Other Criteria: For AD (>=12 yrs) requires diagnosis of moderate-to-severe AD and trial and failure of one of: high-potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine or mycophenolate mofetil; dosing limit for patients <100 kg after 16 weeks: 300 mg every 4 weeks unless rationale provided; Reauthorization requires documentation of positive clinical response; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.
Adempas: Indications: Indications; Coverage Duration: 1 YEAR; Prerequisite Therapy Required: Criteria DOES NOT require use of a prerequisite Part D drug.
Everolimus (TABS / Torpenz): Indications: All medically-accepted indications; Coverage Duration: One Year; Other Criteria: Breast cancer indication requires combination with exemestane and a trial of letrozole or anastrozole; RCC requires a trial of sunitinib or sorafenib; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.
Aimovig: Indications: Indications; Coverage Duration: 1 YEAR; Prerequisite Therapy Required: Criteria DOES NOT require use of a prerequisite Part D drug.
Ebglyss: Indications: All medically-accepted indications; Exclusion: Cannot be used in combination with another biologic or targeted DMARD for same condition; Required medical information: patient must weigh at least 40 kg; Age restriction: at least 12 years; Coverage duration: 1 year; Other: AD for patients >=12 requires diagnosis of moderate-to-severe AD and trial/failure of one of: high-potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine or mycophenolate mofetil; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.>= 12 years
weight >= 40 kg
Eucrisa: Indications: All medically-accepted indications; Coverage duration: 1 year; Other criteria: Coverage for atopic dermatitis requires trial of one of: a topical steroid, generic Protopic, or generic Elidel; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.
Emsam: Coverage duration: 1 year; Other criteria: coverage requires trial with two of: marplan, phenelzine, tranylcypromine; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.
MAOI trial requirement
Epidiolex: Indications: All medically-accepted indications; Coverage duration: 1 year; Other criteria: Lennox-Gastaut syndrome requires trial of 2 generic alternatives for seizures; Dravet syndrome requires trial of 2 of: valproic acid, clobazam, or topiramate; Tuberous sclerosis complex seizures require trial of 2 generic alternatives; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.
Enbrel (and device formulations): Indications: All medically-accepted indications; Exclusion: Cannot be used in combination with another biologic or targeted DMARD indicated for the same condition; Coverage duration: 1 year; Other criteria: RA requires diagnosis of moderately to severely active RA and trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine); JIA polyarticular requires trial of leflunomide or methotrexate; AS requires trial of one NSAID; Reauthorization requires documentation of positive clinical response for all indications; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.
L-glutamine pack: Required medical information: patient has experienced 2 or more sickle cell-related crises in past 12 months; Coverage duration: 1 year; Other criteria: requires trial of or intolerance to hydroxyurea; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.
Topiramate solution: Coverage duration: 1 year; Migraine prevention requires trial of at least 2 generic alternatives OR patient unable to swallow tablets/capsules; Seizure disorder requires trial of at least 2 generic anticonvulsants OR patient unable to swallow tablets/capsules; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.
Pirfenidone (caps/tabs): Coverage duration: 1 year; Prerequisite Therapy Required: Criteria DOES NOT require use of a prerequisite Part D drug.
Forteo / Teriparatide: Required medical information: documentation of bone mineral density T-score at or below -2.5; Coverage duration: 2 years; Other: coverage requires trial of both (1) JUBBONTI or STOBOCLO and (2) either an oral bisphosphonate or, if intolerant, an IV bisphosphonate; Prerequisite Therapy Required: Criteria DOES require use of a prerequisite Part D drug.T-score <= -2.5